AcroCyte Therapeutics, Inc. is a biotechnology company dedicated to overcoming common laboratory challenges through its proprietary R³CE rapid, reproducible, rare cell 3D expansion technology. Recognized with awards such as the Taiwan National Innovation Award, the company focuses on advancing biomedical research and cell-based applications.
Subscribe to see AcroCyte Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
AcroCyte Therapeutics is a biotechnology company headquartered in United States. Its most recent funding round, Grant, closed in July 2026. Xcout tracks 5 named people at AcroCyte Therapeutics, including Ying C. Chang, PhD (Chief Executive Officer and Board Member).
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Grant | Undisclosed | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of AcroCyte Therapeutics's closest competitors — see the full list of competitors and alternatives →
StemCyte is a global cord blood banking and regenerative therapeutics company that provides public and private umbilical cord blood and cord tissue preservation services for expectant families. The company processes, tests, and cryopreserves stem cells for family protection and clinical use, and supplies cellular materials for transplants and medical research.
Bit Bio is a UK biotechnology company that develops technologies for precisely programming human cells, including its opti-ox platform for producing consistent, scalable cell types. It serves biomedical researchers, drug developers, and regenerative-medicine and cell-therapy developers with engineered human cells and related tools.
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.
International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology firm dedicated to creating therapeutic and biomedical solutions for a global market, spanning North America, Asia, Europe, and beyond. Central to its offerings are products derived from its proprietary human parthenogenetic stem cells, a unique form of pluripotent stem cells. ISCO is actively engaged in developing specialized cell types, such as neural stem cells, which hold promise for treating Parkinson's disease and other disorders affecting the central nervous system. Beyond therapeutics, the company also develops, manufactures, and commercializes anti-aging skincare products and an extensive range of human cell culture products. Its diverse portfolio of human cell culture products serves as vital research tools across numerous scientific disciplines. This includes specialized cells and reagents designed for studying: Dermatology: Skin diseases, toxicology, and wound healing. Cardiovascular & Oncology: Heart and blood vessel conditions, and various cancers. Respiratory: Bronchial and tracheal conditions, toxicity, cystic fibrosis, asthma, and pathogenesis. Reproductive & Urological: Prostate, renal, bladder, corneal, and female reproductive system diseases, as well as general cellular physiology. Musculoskeletal & Metabolic: Skeletal muscle biology, diabetes, insulin pathways, muscle repair, and myotube development. The company also provides adult stem cells for regenerative medicine research and a full complement of reagents and supplements essential for cell growth, staining, and cryopreservation. Distribution of ISCO's skincare range occurs via its website and specialized professional channels, while its human cell culture products reach customers through a dedicated sales force, original equipment manufacturer (OEM) partners, and authorized brand distributors. Established in 2001, International Stem Cell Corporation maintains its headquarters in San Diego, California.
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.